Account

Background Heartbeat

CBC South Africa: What Cannabichromene Is, the Law and the Evidence

A scientist handling extract vials in a laboratory, where cannabinoids such as CBC are isolated and tested for CBC South Africa research

Direct answer: In CBC South Africa searches, CBC means cannabichromene, a non-intoxicating cannabinoid made by the cannabis plant. No South African law names it: the 2020 Medicines Act Schedules list only THC and CBD. That gap is not a permission, because plant-derived CBC is still a cannabis product under the Drugs Act and any health claim makes it a medicine. Human evidence is very limited.

Last updated:

Key takeaways

  • CBC is cannabichromene, a cannabinoid the plant makes from cannabigerolic acid; lab and human studies suggest it is not intoxicating.
  • Government Notice R.586 of 22 May 2020 schedules THC (Schedule 6) and CBD (Schedule 4); it does not name CBC.
  • The Drugs and Drug Trafficking Act still lists cannabis and “any portion or product thereof” until Act 7 of 2024 is proclaimed, so plant-derived CBC is not simply unregulated.
  • No randomised trial has tested CBC on its own in people; a 2024 trial of 1,793 adults found adding CBC and CBN to CBD made no significant difference to sleep.
  • Any cannabis medicine a doctor prescribes goes through a registered prescriber and, for unregistered products, a SAHPRA section 21 authorisation.

What is CBC, the cannabinoid?

CBC is short for cannabichromene, one of the cannabinoids the cannabis plant makes alongside THC and CBD. The plant builds it from cannabigerolic acid (CBGA), the same starting molecule behind THC and CBD, using an enzyme called cannabichromenic acid synthase. Heat and time then turn the acid form, CBCA, into CBC.

Japanese researchers led by Morimoto purified that enzyme in 1998 and showed, in the journal Phytochemistry, that it converts cannabigerolic acid into cannabichromenic acid. A 2016 inventory by Hanuš and colleagues in Natural Product Reports names CBC as one of a limited set of major constituents, with CBG, CBD and delta-9-THC and their acid forms, from which much of the plant’s wider chemical diversity may arise through heat, light and oxygen.

How much CBC a plant contains is less clear than product marketing suggests. A 2011 analytical paper called it the second most abundant cannabinoid in cannabis, while a 2026 review in the Journal of Cannabis Research calls it the fourth most abundant in many chemovars. A 2024 review from Penn State notes that most strains produce only small amounts, which is why chemists also make CBC synthetically from citral and olivetol.

A quick note on the search term itself: online, “CBC” more often means the Canadian Broadcasting Corporation or a complete blood count test. This guide is only about cannabichromene. For the wider family of plant cannabinoids, see our guide to phytocannabinoids.

Does CBC get you high?

CBC is not known to be intoxicating. Laboratory studies show it does not activate the CB1 receptor, the brain target behind THC’s high, and a controlled human smoking study found that raising CBC content did not change how people felt or performed. That does not make a product containing CBC free of THC.

In 2019, Udoh and colleagues at Macquarie University and the University of Sydney reported in the British Journal of Pharmacology that CBC activated CB2 but not CB1 receptors in cells, describing it as a selective CB2 agonist. The Penn State review adds that CBC did not block CB1 activation by THC. Our guide to cannabinoid receptors explains why CB1 and CB2 matter.

The human evidence is small but direct. In a 2005 study in Behavioural Pharmacology, 23 experienced users smoked cannabis cigarettes with low or high CBC (0.1 percent against 0.5 percent) under blinded conditions. The authors reported that varying CBC and CBD “did not change subjects’ responses on any of the outcome measures”; the effects came from THC.

Not every scientist reads the receptor data the same way. The 2026 Journal of Cannabis Research review describes minimal direct engagement with CB1 and CB2 and stronger activity at TRP ion channels, consistent with a 2011 study by De Petrocellis and colleagues that found CBC to be a potent agonist of the TRPA1 channel in cells. The mechanism is unsettled.

Close view of resin glands on a cannabis flower, where the plant makes CBC alongside THC and CBD

What does CBC South Africa law actually say?

No South African law names CBC. The Medicines Act Schedules, as amended by Government Notice R.586 of 22 May 2020, list THC in Schedule 6 and CBD in Schedule 4, and are silent on cannabichromene. That silence is a gap, not a permission: plant-derived CBC is still a cannabis product under the drug law in force, and any health claim makes it a medicine.

SAHPRA’s communication on the 2020 notice confirms that “previous entries for cannabis, dronabinol, and tetrahydrocannabinol in Schedule 7 have been deleted”. In their place, CBD is Schedule 4, dropping to Schedule 0 only for low-risk complementary medicines with no more than 600 mg per pack and a 20 mg maximum daily dose, or ingestible processed products with 0,0075 percent CBD or less. THC is Schedule 6, except for low-THC industrial material, processed products with 0,001 percent THC or less, and private adult cultivation and use.

Four features of the law mean the missing name should never be read as “CBC is legal to sell”. First, Schedule 6 of the same notice extends to substances that are chemically related to, or share a structural fragment with, a listed substance. Whether that clause reaches CBC has not, as far as we could find, been tested, and it should not be assumed either way.

Second, the Drugs and Drug Trafficking Act 140 of 1992 still lists “Cannabis (dagga), the whole plant or any portion or product thereof” in Part III of Schedule 2, and it defines manufacture to include extraction. The Cannabis for Private Purposes Act 7 of 2024 deletes that entry, but only from a date the President proclaims under section 8(1). Until then, a CBC extract made from the plant is, on the words of the law, a product of dagga.

Third, plant extracts carry other cannabinoids. A processed product with more than 0,001 percent THC falls into Schedule 6 whatever else is on its label. Fourth, the Medicines Act defines a medicine as any substance used or sold for the treatment, mitigation or prevention of disease or for modifying a bodily function, so a CBC product sold for pain, sleep or inflammation is a medicine that must be registered or authorised.

The 2018 Constitutional Court judgment in Prince protects an adult’s private use and cultivation of cannabis. It does not create a right to buy or sell cannabinoid products. If you need a firm answer on a specific product, ask a legal practitioner; the regulated route for a medical need runs through a doctor, as the sections below explain.

FeatureCBCCBDTHC
Full nameCannabichromeneCannabidiol(-)-trans-delta-9-tetrahydrocannabinol
Named in the Medicines Act Schedules (GN 586, 2020)?NoYes, Schedule 4, with narrow Schedule 0 exceptionsYes, Schedule 6, with narrow exceptions
Intoxicating?Not reported; does not activate CB1 in lab studiesNoYes
Main lab findingActivates CB2 and TRPA1 in cell studiesMany targets; approved seizure medicine abroadPartial agonist at CB1 and CB2
Human trialsNo trial of CBC on its own; one small pharmacokinetic studyRandomised trials in rare epilepsiesRandomised trials for several conditions
Registered medicine in SA?None found in SAHPRA’s published recordsNone registered, per SAHPRA’s 2020 communicationNone registered, per SAHPRA’s 2020 communication

What does the research on cannabichromene actually show?

Almost all CBC research is in cells and animals. Studies suggest possible anti-inflammatory, pain-reducing and anti-seizure effects in mice, but no randomised trial has tested CBC on its own in people. The 2024 Penn State review warns that CBC products are being widely used “with little or no evidence of their safety or efficacy”.

The animal findings are real but narrow. Izzo and colleagues reported in 2012 that CBC normalised inflammation-induced gut hypermotility in mice without affecting normal motility. A 2021 University of Sydney study in a mouse model of Dravet syndrome found that CBC and related compounds raised the temperature at which seizures occurred. A 2024 Penn State study found CBC reduced pain behaviours in mice. None of these tells you what happens in a human body.

Human data are thin. A 2022 pilot study by Peters and colleagues gave 43 people an oral oil containing CBD, a little THC and CBC for seven days and measured blood levels; it suggested CBC may be absorbed preferentially when given with CBD and THC. The study was run by Canopy Growth, which made the product, and it measured absorption, not benefit.

The largest human dataset points the other way on added value. A 2024 randomised trial by Saleska and colleagues in 1,793 adults with poor sleep found that adding a small amount of CBC and CBN to a CBD capsule produced no significant difference compared with CBD alone. The 2026 Journal of Cannabis Research review lists “the absence of clinical trials” among the main obstacles to using CBC as a medicine.

Why should you treat CBC product claims with caution?

Because the label is often the weakest part of a cannabinoid product. Independent testing of CBD products has repeatedly found wrong strengths and undeclared THC, and a CBC product faces the same risks with even less regulation of the specific molecule. A certificate of analysis from an accredited laboratory is the minimum, not proof of benefit.

The best-known test comes from a 2017 research letter in JAMA by Bonn-Miller and colleagues. Of 84 CBD extracts bought online from 31 companies, only 30.95 percent were accurately labelled for CBD, 42.85 percent contained more than stated and 26.19 percent less, and THC was found in 18 of the 84 samples at up to 6.43 mg/mL. No comparable South African test of CBC products exists that we could find.

Those THC findings matter twice here. A CBC oil made from cannabis that carries THC above the 0,001 percent line is a Schedule 6 product, and THC can show up in a workplace drug test. Claims that CBC “treats” pain, acne, depression or cancer have no support from human trials and would, under the Medicines Act definition, make the product an unregistered medicine.

A healthcare worker holding a capsule, a reminder to check any CBC South Africa product claim with a doctor or pharmacist

Before you start

This page is general information for adults aged 18 and over, not medical or legal advice. CBC has not been tested on its own in human clinical trials, so there is no evidence-based dose, and none is given here. Speak to a doctor or pharmacist before using any cannabinoid product, especially if you take other medicines, are pregnant or breastfeeding, or have liver, heart or mental health conditions, and do not stop or change a prescribed medicine on your own.

How would a doctor approach a question about CBC?

A doctor starts with your condition, not the molecule. They consider the evidence for treatments that have been tested, your other medicines and your risks, and only then whether a cannabis medicine is appropriate. Because no CBC medicine is registered, any prescribed cannabis product containing it would normally be supplied under a section 21 authorisation.

Section 21 of the Medicines Act lets SAHPRA authorise, in writing, the sale of a specified quantity of a particular unregistered medicine to a specified person during a specified period, and it may withdraw that authority. In practice the prescriber applies, for a named patient and product. Our step-by-step guide to SAHPRA section 21 explains the process.

Expect the conversation to be about the whole product. A prescribed cannabis oil is defined by its THC and CBD content, which the Schedules regulate; any CBC is a minor constituent. SAHPRA’s own site search returned no published document on cannabichromene when we checked on 19 September 2026. That shows SAHPRA has published nothing about it, not that every product is unlawful.

Tell your doctor about every medicine and supplement you take. The 2026 review notes that CBC is broken down in the liver by cytochrome P450 enzymes, the same family that handles many prescription drugs, and interaction data in people are lacking. For how CBC compares with its closest relatives, see our guides to CBG in South Africa and CBN in South Africa.

How Professor Green fits into the process

Professor Green is a South African medical cannabis access platform and a marketing affiliate of the Dr Green network, which holds the medical cannabis licences. Professor Green does not itself sell, handle or ship cannabis; products are sold and fulfilled by the licensed operator. Professor Green does not sell CBC products and does not diagnose, prescribe, dispense or advise on doses.

Registering gives an adult access to the Professor Green member and store area and the start of the access journey. A registered doctor decides whether a cannabis medicine suits you and, where a product is unregistered, applies for any section 21 authorisation; a licensed pharmacy dispenses. Registration does not guarantee eligibility, a prescription or supply, and no route offers CBC as a stand-alone treatment.

Researching cannabinoids like CBC because you have a health condition and want the regulated, doctor-led route rather than an unlabelled product? You can create your Professor Green account. A registered doctor still assesses you, and registration does not guarantee eligibility, a prescription or supply.

The bottom line on CBC South Africa

Cannabichromene is a real, non-intoxicating cannabinoid with interesting laboratory results and almost no human evidence. For CBC South Africa questions, the honest answer is that no law names it, the drug law in force still covers cannabis products, and any health claim turns a CBC product into a medicine.

If a product promises that CBC treats a condition, treat that as a warning sign. If you have a health condition, the safer next step is a conversation with a doctor about treatments with evidence behind them.

Frequently asked questions

What does CBC stand for in cannabis?
CBC stands for cannabichromene, a cannabinoid made by the cannabis plant from cannabigerolic acid. It is a different molecule from CBD (cannabidiol) and THC. Online, CBC also often means a broadcaster or a complete blood count test, which is unrelated.

Is CBC legal in South Africa?
No South African law names CBC. The 2020 Schedules list THC and CBD only, but the Drugs and Drug Trafficking Act still lists cannabis and any product of it, and a CBC product sold with a health claim is a medicine. Ask a legal practitioner about a specific product.

Does CBC get you high?
CBC is not known to be intoxicating. It does not activate the CB1 receptor in lab studies, and a 2005 human study found that changing CBC content did not change how people felt. A CBC product can still contain THC, so check an accredited lab report.

Is CBC better than CBD?
There is no evidence that it is. CBD has randomised trials behind an approved seizure medicine abroad, while CBC has none on its own. A 2024 trial in 1,793 adults found adding CBC and CBN to CBD made no significant difference to sleep.

Can a doctor prescribe CBC in South Africa?
No CBC medicine is registered, so a doctor cannot prescribe a registered CBC product. A doctor may prescribe a cannabis medicine that contains some CBC, usually under a SAHPRA section 21 authorisation for a named patient, if it suits your condition.

What is the CBC South Africa legal position for importing products?
Importing a plant-derived CBC product can involve the Drugs and Drug Trafficking Act, which lists cannabis products, and the Medicines Act if it makes health claims or contains THC or CBD above the Schedule limits. Take legal advice before importing any cannabinoid product.

Does Professor Green sell CBC products?
No. Professor Green is a medical cannabis access platform and a marketing affiliate of the Dr Green network. It does not sell, handle or ship cannabis, and it does not diagnose, prescribe or advise on doses. A registered doctor decides on any prescription.

Sources and references

Legal points are paraphrased from the Acts, the Government Gazette notice and SAHPRA’s communication as read on 19 September 2026; research findings are attributed to the studies above. This is general information for adults aged 18 and over, not medical or legal advice, and contains no dosing guidance. For a view on a specific product, consult a legal practitioner; for a health condition, consult a registered doctor.

Exploring cannabinoids like CBC for a health condition?

If you have been researching CBC South Africa rules and want the regulated route, where a registered doctor weighs the evidence and your other medicines before anything is prescribed, you can create a Professor Green account. Registration is the next step, not a guarantee of eligibility, a prescription or supply.

Create Your Professor Green Account
Share the Post:

Related Posts

Professorgreen.co.za is ran by Green Tec LLC is an authorised marketing affiliate for the Dr Green network who holds the Medical Cannabis licences in South Africa. We do not sell, handle, or ship cannabis. All cannabis products are sold and fulfilled by licensed operator DR Green.

Our Social